The U.S. depends on China for 80-90% of active pharmaceutical ingredient production for antibiotics and other essential medicines, creating a national security vulnerability

The United States has lost nearly all domestic capacity to produce active pharmaceutical ingredients (APIs) for critical drug classes, with China controlling 80-90% of global API production for antibiotics and other essential compounds. India, which supplies 70-80% of U.S. generic drugs, itself depends on China for approximately 70% of its bulk drug and intermediate imports, creating a fragile two-tier dependency. Why it matters: in 2024 the U.S. imported 828,000 metric tons of pharmaceuticals (7x the 2000 level), so any trade disruption, geopolitical conflict, or export restriction by China could create immediate drug shortages for essential medications, so the U.S. pharmaceutical supply chain has a single catastrophic point of failure for antibiotics, blood pressure medications, and other critical drugs, so even India's role as an alternative supplier is undermined because 87% of India's imported antibiotic ingredients by value came from China in 2024 (up from 60% in the mid-2000s), so the entire global generic drug supply is ultimately dependent on Chinese chemical manufacturing capacity and willingness to export. The structural root cause is that China systematically subsidized its API manufacturing sector with cheap energy, lax environmental enforcement, and state-backed overcapacity to undercut Western and Indian producers on price, driving competitors out of the market over two decades -- and no U.S. policy mechanism (tariffs, reshoring incentives, or strategic stockpiling) has yet reversed this dependency at meaningful scale.